Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) PT at $41.75

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $41.75.

ASMB has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, December 22nd.

Assembly Biosciences Stock Up 3.5%

ASMB stock opened at $28.46 on Wednesday. The firm has a market capitalization of $450.24 million, a PE ratio of -38.46 and a beta of 1.11. Assembly Biosciences has a twelve month low of $7.75 and a twelve month high of $39.71. The stock has a 50-day simple moving average of $28.16 and a two-hundred day simple moving average of $29.58.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share for the quarter, beating the consensus estimate of ($0.51) by $2.99. Assembly Biosciences had a negative return on equity of 8.06% and a negative net margin of 8.47%.The firm had revenue of $42.47 million for the quarter, compared to analysts’ expectations of $7.42 million. On average, equities research analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in ASMB. Seven Fleet Capital Management LP bought a new stake in Assembly Biosciences during the fourth quarter valued at $147,000. Virtus Investment Advisers LLC bought a new position in Assembly Biosciences in the 4th quarter worth about $251,000. Susquehanna Portfolio Strategies LLC bought a new position in Assembly Biosciences in the 4th quarter worth about $473,000. Superstring Capital Management LP purchased a new stake in shares of Assembly Biosciences in the 4th quarter valued at about $2,220,000. Finally, Millennium Management LLC raised its holdings in shares of Assembly Biosciences by 354.6% in the 4th quarter. Millennium Management LLC now owns 98,221 shares of the biopharmaceutical company’s stock valued at $3,340,000 after acquiring an additional 76,613 shares in the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.